# Patent Watch: Esolate Targets Solid Oral CBD Formulations

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/patent-watch-patent-watch-esolate-targets-solid-oral-cbd-f-2026-10-09/
> **Published:** 2026-10-09T23:28:01-04:00 | **Last Modified / Clinically Audited:** 2026-10-09T23:28:01-04:00
> **Clinical Summary:** US20260097052A1 describes pharmaceutical formulations containing cannabidiol (CBD), including solid oral dosage forms, along with manufacturing methods and

---

PATENT WATCH
 US20260097052A1
 
 

# Patent Watch: Esolate Targets Solid Oral CBD Formulations

 
 **Assignee:** Esolate Pharmaceuticals Ltd
 **Inventors:** Hardin Matthew Jackson, Devin Douglas Machin, Jinhee Oh, Venkat Reddy Goskonda, Andrew Jonathan Saich
 **Published:** 2026-04-09
 
 

 
 Invention Summary & Claims
 

US20260097052A1 describes pharmaceutical formulations containing cannabidiol (CBD), including solid oral dosage forms, along with manufacturing methods and therapeutic uses. CBD is the active pharmaceutical ingredient, while the available disclosure does not identify specific excipients, release mechanisms, doses, or targeted clinical indications.

 

 

## Clinical Perspective & Therapeutic Significance

 

A well-developed solid oral CBD product could offer convenient administration and reproducible dosing, but improved absorption or reduced variability cannot be inferred from dosage form alone. CBD is generally non-intoxicating, yet it can cause adverse effects and [drug interactions](https://cedclinic.com/cbd-male-enhancement-gummies-safety-know-before-trying/), so any new formulation would require product-specific safety and pharmacokinetic evaluation.

 

## Intellectual Property & Market Landscape

 

Esolate Pharmaceuticals Ltd is the named applicant, and the application positions CBD within pharmaceutical formulation development rather than conventional consumer cannabis branding. Compared with common CBD oils, gummies, and capsules, meaningful differentiation would depend on the specific formulation claims, manufacturing controls, and supporting performance data.

 
 **Official Source Document:** Review the primary patent disclosure and full claims on [Google Patents (US20260097052A1)](https://patents.google.com/patent/US20260097052A1/en).
 

 
 Editorial Commentary
 

The clinically meaningful question is whether this formulation delivers measurable advantages over existing oral CBD products. Intellectual property claims alone do not establish better absorption, safer treatment, or effectiveness for additional conditions.

 

 
 

### Frequently Asked Questions

 
 Would a solid oral [CBD formulation](https://cedclinic.com/green-otter-cbd-gummies-copd-evidence/) work better than CBD oil?
 Not necessarily. Comparative studies would need to show whether the specific formulation changes absorption, dosing consistency, tolerability, or clinical outcomes.

 Does this patent publication mean the formulation has passed clinical trials?
 No. A published patent application describes intellectual property claims and does not establish successful clinical trials, regulatory approval, or even an issued patent.

 When could patients obtain a product based on this application?
 The disclosure does not establish a commercial launch date or current availability. Availability would depend on development progress, manufacturing readiness, and the applicable regulatory pathway.

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.
 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Cannabis Consultation](https://cedclinic.com/book/)
 
 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).